Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid: Synergy through modulation of interleukin-6 autocrine loop at multiple sites

Blood

Volumn 87, Issue 1, 1996, Pages 314-323

  Chen, Yi Hsiang ^a   Desai, Pratibha ^b   Shiao, Rei Tsang ^b   Lavelle, Donald ^b   Haleem, Abdul ^b   Chen, Jennie ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DEXAMETHASONE SODIUM PHOSPHATE; DOXORUBICIN; GLUCOCORTICOID; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PREDNISONE; RECOMBINANT INTERLEUKIN 6; RETINOIC ACID; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL GROWTH; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; DRUG MIXTURE; DRUG POTENTIATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; RECEPTOR DENSITY;

EID: 0030034746     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.1.314.bloodjournal871314     Document Type: Article

References (54)

1. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 330:484, 1994
2. Gregory WM, Richards MA, Malpas JS: Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials. J Clin Oncol 10:334, 1992
3. Jagannath S, Vesole DH, Glenn L, Crowely J, Barlogie B: Low risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 80:1666, 1992
4. Fermand J-P, Chevert S, Ravaud P, Divine M, Leblond V, Dreyfus F, Mariette X, Brouet J-C: High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: Results of a phase II trial involving 63 patients. Blood 82:2005, 1993
5. Anderson KC, Barut BA, Ritz J, Freeman AS, Takvorian T, Rabinowe SN, Soiffer R, Heflin L, Coral F, Dear K, Mauch P, Nadler LM: Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood 77:712, 1991
6. Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M, Facon T, Granena A, Gore M, Gratwohl A, Lowenberg B, Nikoskelainen J, Feiffers JJ, Samson D, Verdonck L, Volin L, for the European Group for Bone Marrow Transplantation: Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 325:1267, 1991
7. Klein B, Zhang XG, Lu ZY, Bataille R: Interleukin-6 in human multiple myeloma. Blood 85:863, 1995
8. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T: Autocrine generation and requirement of BSF-2/IL-6 for human myelomas. Nature 332:83, 1988
9. Freeman GJ, Freeman AS, Rabinowe SN, Segil JM, Horowitz J, Rosen K, Whitman JF, Nadler LM: Interleukin 6 gene expression in normal and neoplastic B cells. J Clin Invest 83:1512, 1989
10. Anderson KC, Jones RM, Morimoto C, Leavitt P, Barut BA: Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 73:1915, 1989
11. Schwab G, Siegall CB, Aarden LA, Neckers LM, Nordan RP: Characterization of an interleukin-6-mediated autocrine growth loop in the human myeloma cell line, U266. Blood 77:587, 1991
12. Hitzler JK, Martinez-Valdez H, Bergsagel DB, Minden MD, Messner HA: Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease. Blood 78:1996, 1991
13. Levy Y, Tsapis A, Brouet J-C: Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. J Clin Invest 88:696, 1991
14. Klein B, Wijdenes J, Zhang X-G, Jourdan M, Boiron J-M, Brochier J, Liautard J, Merlin M, Clement C, Morel-Fournier B, Lu Z-Y, Mannoni P, Sany J, Bataille R: Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78:1198, 1991
15. Klein B, Zhang X-G, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R: Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73:517, 1989
16. Caligaris-Cappio F, Bergui L, Gregoretti MG, Gaidano G, Gaboli M, Schena M, Zallone AZ, Marchisio PC: Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 77:2688, 1991
17. Salmon SE, Shadduck RK, Schilling A: Intermittent high dose prednisone therapy for multiple myeloma. Cancer Chemother Rep 51:179, 1967
18. McIntyre OS, Pajak TF, Kyle RA, Cornwell GG III, Leone L, for the Cancer and Leukemia Group B: Response rate and survival in myeloma patients receiving prednisone alone. Med Pediatr Oncol 13:239, 1985
19. Alexanian R, Barlogie B, Dixon D: High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 105:8, 1986
20. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B: Primary dexamethasone treatment of multiple myeloma. Blood 80.887, 1992
21. Chen Y, Feng X-X, Schilder L: Effect of vincristine, adriamycin, and glucocorticoids on myeloma cells in vitro Acta Haematol 89:61, 1993
22. Tobler A, Meier R, Seitz M, Dewald B, Baggiolini M, Fay MF: Glucocorticoids down regulate gene expression of GM-CSF. NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts. Blood 79:45, 1992
23. Ishikawa H, Tanaka H, Iwato K, Tanabe O, Asaoku H, Nobuyoshi M, Yamamoto I, Kawano M, Kuramoto A: Effect of glucocorticoids on the biologic activities of myeloma cells: Inhibition of interleukin-1β osteoclast activating factor-induced bone resorption. Blood 75:715, 1990
24. Akira S, Taga T, Kishimoto T: Interleukin-6 in biology and medicine. Adv Immunol 54:1, 1993
25. Sidell N, Taga T, Hirano T, Kishimoto T, Saxon A: Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. J Immunol 146:3809, 1991
26. Ogata A, Nishimoto N, Shima Y, Yoshizaki K, Kishimoto T: Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction. Blood 84:3040, 1994
27. Gonchoroff NJ, Greipp PR, Kyle RA, Katzmann JA: A monoclonal antibody reactive with 5-bromo-2-deoxyuridine that does not require DNA denaturation. Cytometry 6:506, 1985
28. Vindelov LL, Christensen IJ, Nissen NI: A detergent method for the preparation of nuclei for flow-cytometric DNA analysis. Cytometry 3:323, 1983
29. Chirgwin JJ, Przybla AE, MacDonald RJ, Rutter WJ: Isolation of biologically active RNA from sources enriched in ribonuclease. Biochemistry 18:5294, 1979
30. Brenner CA, Tam AW, Nelson PA, Engleman EG, Suzuki N, Fry KE, Larrick JW: Message amplification phenotyping (MAP-Ping): A technique to simultaneously measure multiple mRNA from small numbers of cells. Biotechniques 7:1096, 1989
31. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Mstsuda T, Kashiwamura S, Nakiyama K, Koyama K, Iwamatsu F, Matsui H, Takahara Y, Taniguchi T, Kishimoto T: Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324:73, 1986
32. Meyers, FJ, Gurnerlock PH, Kawasaki E, Wang AM, deVere White RW, Erlich H: Bladder cancer: Human leukocyte antigen II, interleukin-6 and interleukin-6 receptor expression determined by polymerase chain reaction. Cancer 67:2087, 1991
33. Inoue K, Sugiyama H, Ogawa H, Yamaguchi T, Azuma T, Oka Y, Miwa H, Kita K, Hiraoka A, Masaoka T, Nasu K, Kyo T, Dohy H, Hara J, Kanamaru A, Kishimoto T: Expression of the interleukin-6 (IL-6), IL-6 receptor, and gp130 genes in acute leukemia. Blood 84:2672, 1994
34. Nakajima-Iijima S, Hamada H, Reddy P, Kakunaga T: Molecular structure of the human cytoplasmic β-actin gene: Interspecies homology of sequences in the introns. Proc Natl Acad Sci USA 82:6133, 1985
35. Ballagi-Pordany A, Ballagi-Pordany A, Funa K: Quantitative determination of mRNA phenotypes by the polymerase chain reaction. Anal Biochem 196:89, 1991
36. Becker S, Quay J, Soukup J: Cytokine (tumor necrosis factor, IL-6, and IL-8) production by respiratory syncytial virus-infected human alveolar macrophages. J Immunol 147:4307, 1991
37. Taga T, Kawanishi Y, Hardy RR, Hirano T, Kishimoto T: Receptors for B cell stimulatory factor 2. Quantitation, specificity, distribution, and regulation of their expression. J Exp Med 166:967, 1987
38. Scatchard G: The attractions of proteins for small molecules and ions. Ann NY Acad Sci 51.660, 1949
39. 2-terminal amino acid sequence of a new T cell-derived lymphokine with growth factor activity for B cell hybridomas. Proc Nat Acad Sci USA 83:9679, 1986
40. Barenbaum MC: What is synergy? Pharmacol Rev 41:93, 1989
41. Chou T-C, Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul 22:27, 1984
42. Durie BGM, Vela E, Baum V, Leibovitz A, Payne CM, Richter LC, Grogan TM, Trent JM: Establishment of two new myeloma cell lines from bilateral pleural effusions: Evidence for sequential in vivo clonal change. Blood 66:548, 1985
43. Yamasaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y, Seed B, Taniguchi T, Hirano T, Kishimoto T: Cloning and expression of the human interleukin-6 (BSF-2/IFNβ 2) receptor. Science 241:825, 1988
44. Moali PA, Pillay S, Weiner D, Leikin R, Rosen ST: A mechanism of resistance to glucocorticoids in multiple myeloma: Transient expression of a truncated glucocorticoid receptor mRNA. Blood 79:213, 1992
45. Okuno Y, Takahashi T, Suzuki A, Ichiba S, Nakamura K, Okada T, Okada H, Imura H: In vitro growth pattern of myeloma cells in liquid suspension or semi-solid culture containing interleukin-6. Int J Hematol 54:41, 1991
46. Montes-Borinaga A, Millar BC, Bell JBG, Joffe JK, Millar JL, Gooding R, Riches P, McElwain TJ: Interleukin-6 is a cofactor for the growth of myeloma cells from human bone marrow aspirates but does not affect the clonogenicity on myeloma cells in vitro. Br J Haematol 76:476, 1990
47. Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R, Epstein J: Interleukin-6 gene expression in multiple myeloma: A characteristic of immature tumor cells. Blood 81:3357, 1993
48. Durie BGM, Young LA, Salmon SE: Human myeloma in vitro colony growth: Interrelationships between drug sensitivity, cell kinetics, and patient survival duration. Blood 61:929, 1983
49. Caligaris-Cappio F, Bergui L, Tesio L, Pizzolo G, Malavasi F, Chilosi M, Campana K, van Camp B, Janossy G: Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. J Clin Invest 76:1243, 1985
50. Bergui L, Schena M, Gaidano G, Riva M, Caligaris-Cappio F: Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J Exp Med 170:613, 1989
51. Muindi JRF, Franke SR, Huselton C, DeGrazia F, Garland WA, Young CW, Warrell RP Jr: Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 52:2138, 1992
52. Chen Y, Desai P, Haleem A, Chen J: Enhanced growth inhibitory effect of all-trans retinoic acid and dexamethasone combination on human myeloma cell lines. Blood 82:260a, 1993 (abstr, suppl 1)
53. Vesole D, Kornbluth J, Jagannath S, Sznol M, Mattox S, Vaught L, Tricot G, Barlogie B: Biological response modifiers in refractory multiple myeloma: Lack of clinical efficacy of recombinant human interleukin-4 and all-trans retinoic acid. Blood 82:263a, 1993 (abstr, suppl 1)
54. Zitnik RJ, Kotloff RM, Latifpour J, Zheng T, Whiting NL, Schwalb J, Elias JA: Relinoic acid inhibition of IL-1-induced IL-6 production by human lung fibroblasts. J Immunol 152:1419, 1994